CN104127594A - Phytoextraction composition applied to prevention and control of diabetes - Google Patents
Phytoextraction composition applied to prevention and control of diabetes Download PDFInfo
- Publication number
- CN104127594A CN104127594A CN201410401737.4A CN201410401737A CN104127594A CN 104127594 A CN104127594 A CN 104127594A CN 201410401737 A CN201410401737 A CN 201410401737A CN 104127594 A CN104127594 A CN 104127594A
- Authority
- CN
- China
- Prior art keywords
- control
- diabetes
- prevention
- plant extract
- diabetes mellitus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 230000002265 prevention Effects 0.000 title claims abstract description 16
- 244000269722 Thea sinensis Species 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 7
- 240000006914 Aspalathus linearis Species 0.000 claims abstract description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 6
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 6
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 3
- 239000000419 plant extract Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 235000009392 Vitis Nutrition 0.000 claims description 5
- 241000219095 Vitis Species 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 235000012984 Aspalathus linearis Nutrition 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 229930014669 anthocyanidin Natural products 0.000 claims description 2
- 150000001452 anthocyanidin derivatives Chemical class 0.000 claims description 2
- 235000008758 anthocyanidins Nutrition 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract description 4
- 230000037396 body weight Effects 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229930002877 anthocyanin Natural products 0.000 abstract 1
- 235000010208 anthocyanin Nutrition 0.000 abstract 1
- 239000004410 anthocyanin Substances 0.000 abstract 1
- 150000004636 anthocyanins Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229940087603 grape seed extract Drugs 0.000 abstract 1
- 235000002532 grape seed extract Nutrition 0.000 abstract 1
- 235000020627 health maintaining nutrition Nutrition 0.000 abstract 1
- 230000002000 scavenging effect Effects 0.000 abstract 1
- 239000001717 vitis vinifera seed extract Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 9
- 235000001727 glucose Nutrition 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 235000013616 tea Nutrition 0.000 description 4
- 235000006468 Thea sinensis Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 235000020279 black tea Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 102000030595 Glucokinase Human genes 0.000 description 2
- 108010021582 Glucokinase Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical class O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a phytoextraction composition applied to prevention and control of diabetes. The phytoextraction composition comprises the following active ingredients in parts by weight: 1-8 parts of dietary fiber, 0.01-0.3 part of anthocyanin-containing grape seed extract, and 0.001-0.5 part of tea polyphenol-containing Rooibos red tea extract. The combination is conducted on the basis of the aspects of scavenging human free radicals, protecting beta cells and controlling body weight and preventing complications, thus providing a healthy nutrition product or a drug for prevention and control for patients with diabetes and the high-risk crowds.
Description
[technical field]
The present invention relates to the compositions of diabetes mellitus prevention and control, be specifically related to a kind of plant extract compositions that is applied to diabetes mellitus prevention and control.
[background technology]
Diabetology branch of Chinese Medical Association in 2013 announces Diabetes Epidemiological Investigation more than 30 years old crowd of result China diabetes prevalence and reaches 11.6%, estimates that there are 1.39 hundred million diabeticss in the whole nation.Become the first in the world diabetes big country.
The intervention of diabetes life style is mainly by adequate diet and takes exercise and reduce body weight (being greater than the 7-8.5% of 6 kilograms or body weight) and control blood glucose.If pre-diabetes crowd could not life style intervention control process, will become diabetics.In the whole diabeticss of the U.S., 16% also can be by the life style intervention control state of an illness, and other 86% just must adopt therapeutic treatment on the basis of life style intervention.
The sick complication of diabetic urine is the main harm place of diabetes.Hyperglycemia state has material impact to multiple organ/system, wherein particularly remarkable on microcirculatory impact, mostly microcirculation complication (diabetic ophthalmopathy, nephropathy, CHD, peripheral neuropathy are as ulcer of foot etc.) is the diabetic complication occurring the earliest, it is even usually the reason that patient seeks medical advice for the first time, patient's diabetic duration before this may be as long as five years or is longer, just there is no a discovery due to asymptomatic.
Meanwhile, scientific research is found:
In Semen Vitis viniferae, contain polyphenols (GPS), mainly contain catechin and procyanidin class.Procyanidin, is called for short OPC, is a kind of bioflavonoids that has special molecular structure, is the at present generally acknowledged the most effective Natural antioxidant of removing people interior free yl in the world.
South Africa black tea, has another name called Rooibos (roy-boss) or " African Red shrub tea ", is that the unique another kind in the world need be via " the tea product " of fermentation processing procedure as black tea.Due to without caffeine, low tannic acid, the sweet composition of natural increasing and abundant mineral, deeply drunk liking of people.South Africa and Japanese scientific research more confirm, Rooibos is containing abundant antioxidant, and have the polyphenol content more than green tea, more point out its for anti-machine because of sudden change, anticancer, anti-inflammatory and antiviral particular utility.
Due to oxygen-derived free radicals in the process of onset diabetes and development, play the part of in important " killer " role, thereby remove oxygen-derived free radicals, reduce oxygen and coerce, improve islet cells activities of antioxidant enzymes very important for the prognosis of diabetes.Antioxidant can effectively be removed the polyradical of crossing producing in body, and protection beta Cell of islet is avoided free radical infringement.On the other hand, can strengthen kinase activity.Glucokinase is the isozyme of hexokinase, is mainly present in ripe hepatic parenchymal cells and beta Cell of islet, regulated by insulin, and catalysis glucose changes G6P into, and then forms hepatic glycogen, thereby reduces blood glucose.Antioxidant effectively reduces blood glucose by antioxidation with strengthening glucokinase.
[summary of the invention]
The object of the invention is to utilize the above-mentioned characteristic of Semen Vitis viniferae and South Africa black tea prevent for diabetes and control.
Be applied to a plant extract compositions for diabetes mellitus prevention and control, comprise the dietary fiber of 1～8 weight portion, contain the Semen Vitis viniferae extract of anthocyanidin 0.01～0.3 weight portion and the African Red tea extract containing tea polyphenols 0.001～0.5 weight portion.
Said composition can further include excipient.
Above-mentioned plant extract compositions is for the manufacture of diabetes mellitus prevention and the application of controlling in medicine.
Described medicine is tablet, powder, granule or powder preparation to be taken after being infused in boiling water, capsule.
Above-mentioned plant extract compositions is for the manufacture of the application in the dietary supplement of diabetes mellitus prevention and control.
Described supplement are oral administration preparation, food product, beverage or nutriment.
The present invention is based on and remove interior free yl, protect β cell and control body weight and complication prevention aspect to combine, is that diabetics and High risk group improve a kind of prevention and control health-nutrition product or medicine.
[brief description of the drawings]
Fig. 1 is the fasting blood sugar of separate groups of mice;
Fig. 2 is the random blood sugar value of separate groups of mice;
Fig. 3 is the postprandial plasma glucose level of separate groups of mice;
Fig. 4 is the OGTT result of separate groups of mice.
[detailed description of the invention]
Further illustrate the present invention below by an embodiment.It should be understood that embodiments of the invention are for this aspect instead of limitation of the present invention are described, all belong to the claimed category in this aspect according to the essence of this aspect to simple modification of the present invention.
Embodiment 1
Tablet: in weight portion, get 53 parts of dietary celluloses (commercially available soybean cellulose), 2 parts of Semen Vitis viniferae extracts (OPC is greater than 95%), 5 parts of African Red tea extracts (tea polyphenols is greater than 70%), the binding agent taking water as solvent is made wet granular; Wet granular is sieved through 10-40 order; Granule after sieving is dry at 20-80 DEG C; Dried granule is compressing through tablet machine.Every 300mg.
Choose 20 of type ii diabetes KKAy mouse models in female 8 week age, adaptability was fed after 7 days, confirmed, after KKAy mice obesity, to be divided at random several groups.
Each treated animal is raised (room temperature is 20-26 DEG C, humidity 40-70%, the day-night cycle of 14/10 hour) free diet drinking-water under SPF (specific pathogen free microorganism) environment.Adopt extraction compositions gavage of the present invention every day, continuous one month.
Weigh weekly the weight of animals, fasting glucose (fasting be can't help, after water 6h, cutting tail and getting blood, and rapid blood sugar instrument is measured)/carbohydrate tolerance experiment (OGTT) (after fasting 6h, giving 2g/kg glucose gavage); Analytical balance takes liver weight and calculates dirty body ratio.
Adopt T inspection to carry out data analysis, p<0.05, for having significance.
Blood glucose (experiment of fasting glucose/random blood sugar/2 hours blood glucoses after the meal/carbohydrate tolerance)
High lipid food is fed the easy blood glucose of suffering from type-II diabetes kkay mice of induction and is significantly raise, as shown in Figure 1,2 and 3, after gavage extraction compositions of the present invention, can significantly reduce the blood glucose (fasting glucose of kkay mice, random blood sugar, post-prandial glycemia).Impaired glucose tolerance is the necessary stage in early stage of type ii diabetes, and Fig. 4 shows that the kkay glucose tolerance in mice of high fat induction is impaired, regulates the ability of blood glucose to reduce, instruction insulin resistant, and give the kkay glucose tolerance in mice after each formula impaired alleviating.
Claims (6)
1. one kind is applied to the plant extract compositions of diabetes mellitus prevention and control, it is characterized in that comprising the dietary fiber of 1～8 weight portion, contain the Semen Vitis viniferae extract of anthocyanidin 0.01～0.3 weight portion and the African Red tea extract containing tea polyphenols 0.001～0.5 weight portion.
2. the plant extract of diabetes mellitus prevention as claimed in claim 1 and control combination, characterized by further comprising excipient.
Described in a claim 1 plant extract compositions for the manufacture of diabetes mellitus prevention and the application of controlling in medicine.
4. plant extract compositions as claimed in claim 3, for the manufacture of the application in the medicine of diabetes mellitus prevention and control, is characterized in that described medicine is tablet, powder, granule or powder preparation to be taken after being infused in boiling water, capsule.
5. the application in the dietary supplement that described in a claim 1, plant extract compositions is controlled for the manufacture of diabetes mellitus prevention and control.
6. plant extract compositions, for the manufacture of the application in the dietary supplement of controlling, is characterized in that described supplement are oral administration preparation, food product, beverage or nutriment as claimed in claim 5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410401737.4A CN104127594A (en) | 2014-08-14 | 2014-08-14 | Phytoextraction composition applied to prevention and control of diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410401737.4A CN104127594A (en) | 2014-08-14 | 2014-08-14 | Phytoextraction composition applied to prevention and control of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104127594A true CN104127594A (en) | 2014-11-05 |
Family
ID=51800616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410401737.4A Pending CN104127594A (en) | 2014-08-14 | 2014-08-14 | Phytoextraction composition applied to prevention and control of diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104127594A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107307417A (en) * | 2017-06-17 | 2017-11-03 | 深圳市领治医学科技有限公司 | A kind of type 2 diabetes patient's nutriment |
| WO2018184523A1 (en) * | 2017-04-03 | 2018-10-11 | 大江生医股份有限公司 | Composition capable of promoting testosterone secretion and use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1457689A (en) * | 2003-05-15 | 2003-11-26 | 高景曦 | Function food with diet fibre and anthocyanidin |
| EP1640001A1 (en) * | 2004-09-24 | 2006-03-29 | New Pharma Investments Holding | Composition against cardiovascular diseases |
| CN102458155A (en) * | 2009-05-29 | 2012-05-16 | 雀巢产品技术援助有限公司 | Green tea extracts of improved bioavailability |
-
2014
- 2014-08-14 CN CN201410401737.4A patent/CN104127594A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1457689A (en) * | 2003-05-15 | 2003-11-26 | 高景曦 | Function food with diet fibre and anthocyanidin |
| EP1640001A1 (en) * | 2004-09-24 | 2006-03-29 | New Pharma Investments Holding | Composition against cardiovascular diseases |
| CN102458155A (en) * | 2009-05-29 | 2012-05-16 | 雀巢产品技术援助有限公司 | Green tea extracts of improved bioavailability |
Non-Patent Citations (5)
| Title |
|---|
| 卢尔滨: "《把中国人的营养装进"盘子"》", 31 October 2013, 吉林科学技术出版社 * |
| 李宏梁: "《食品添加剂安全与应用》", 31 August 2012, 化学工业出版社 * |
| 柴瑞震: "《糖尿病饮食宜忌慎随身查》", 30 November 2013, 黑龙江科学技术出版社 * |
| 范小振等: "《生活中的绿色化学》", 31 January 2014, 河北大学出版社 * |
| 许利嘉等: "南非红茶的研究进展", 《现代药物与临床》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018184523A1 (en) * | 2017-04-03 | 2018-10-11 | 大江生医股份有限公司 | Composition capable of promoting testosterone secretion and use thereof |
| CN110494150A (en) * | 2017-04-03 | 2019-11-22 | 大江生医股份有限公司 | A kind of composition and application thereof can promote the secretion of testis sterone |
| US11806317B2 (en) | 2017-04-03 | 2023-11-07 | Tci Co., Ltd. | Composition capable of promoting testosterone secretion and use thereof |
| CN107307417A (en) * | 2017-06-17 | 2017-11-03 | 深圳市领治医学科技有限公司 | A kind of type 2 diabetes patient's nutriment |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Cordycepin from Cordyceps militaris prevents hyperglycemia in alloxan-induced diabetic mice | |
| JP5638180B2 (en) | Foods containing Salacia plant extracts and flavonoids | |
| CN107412341A (en) | A kind of hypoglycemic formula containing blue or green money willow and preparation method thereof | |
| CN108420854B (en) | Antifatigue composition for improving endurance performance | |
| CN105053420A (en) | Blood sugar reducing tea | |
| JP2012207009A (en) | Method for producing mulberry twig pulverized powder | |
| KR20160007728A (en) | Method for manufacturing garlic skin extract and food composition for preventing and alleviating diabetes prepared using the same | |
| CN108497498A (en) | A kind of functional food of relieving alcoholism and protecting liver and preparation method thereof | |
| Nwaoguikpe | The effect of extract of bitter leaf (Vernonia amygdalina) on blood glucose levels of diabetic rats | |
| CN104523742B (en) | A kind of polysaccharide composition and its application with protect liver and raising immunization | |
| CN106955297B (en) | Cistanche tubulosa extract and application of isoacteoside in muscle protection | |
| CN106421208B (en) | Pharmaceutical composition with chemical liver injury resistance function and preparation method thereof | |
| Hussain et al. | Comparative in vitro analysis of anti-diabetic activity of Indo-Pak black cardamom (Amomum subulatum Roxb.) and Chinese black cardamom (Amomum tsao-ko Crevost et Lemaire) | |
| CN104127594A (en) | Phytoextraction composition applied to prevention and control of diabetes | |
| CN102068475B (en) | Application and blood-sugar lowering effective part of trapa acornis nakano shell as well as extraction method of blood-sugar lowering effective part | |
| CN103005436B (en) | Mulberry resource auxiliary blood sugar decreasing health food and preparation method thereof | |
| CN105106300A (en) | Use of cyclocarya paliurus extract in preparation of drug for preventing and treating non-alcoholic fatty liver disease | |
| JP2014239699A (en) | Blood adiponectin amount increasing agent | |
| CN102861114A (en) | Kiwi fruit extract and extraction method and application thereof | |
| KR101467407B1 (en) | Antidiabetic food composition with the extract of Dendropanax morbifera | |
| JP2004331635A (en) | Cytogenetic information normalization material and method for preparing the same | |
| JP2010043036A (en) | Saccharometabolism promoter | |
| CN101596268B (en) | Application of garlic total saponin in preparing medicaments and foods for resisting oxidative stress damage | |
| CN105455120A (en) | Golden camellia tea assisted blood sugar lowering capsule | |
| CN109966283A (en) | Application of the degreasing cinnamon polyphenol extract in preparation prevention and treatment diabetic nephropathy product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170929 Address after: Haicang District of Xiamen City, Fujian province 361000 Weng Kok Road No. 2052 Haicang Biomedical Industry Park No. 2 floor third unit 03 Applicant after: Xiamen set biological medicine technology Co., Ltd. Address before: 450004 Henan Province, Zhengzhou City Road No. 11 Building No. 1 Hospital No. 14 Applicant before: Sun Zhanqiang |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141105 |
|
| RJ01 | Rejection of invention patent application after publication |